Polymer-conjugated guanidine is a potentially useful anti-tumor agent

International Journal of Oncology

Volumn 35, Issue 2, 2009, Pages 281-285

  Meurling, Lennart ^a   Marquez, Marcela ^a   Nilsson, Sten ^a   Holmberg, Anders R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti tumor; Conjugates; Dextran; Guanidine

Indexed keywords

AGMATINE; AMINOGUANIDINE; DEXTRAN; DOXORUBICIN; POLYMER; ANTINEOPLASTIC AGENT; GUANIDINE; POLYAMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL DESTRUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEXTRANS; GUANIDINE; HUMANS; POLYAMINES;

EID: 69449083366     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000338     Document Type: Article

References (26)

1. Nilsson BL and Overman LE: Concise synthesis of guanidinecontaining heterocycles using the Biginelli reaction. J Org Chem 71: 7706-7714, 2006.
2. Thornalley PJ: Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation end products. Arch Biochem Biophys 419: 31-40, 2003.
3. Sell DR, Nelson JF and Monnier VM: Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fisher 344 rat. J Gerontol Biol Sci 56: 405-411, 2001.
4. Scaccini C, Chiesa G and Jialal I: A critical assessment of the effects of aminoguanidine and ascorbate on the oxidative modification of LDL: evidence for interference with some assays of lipoprotein oxidation by aminoguanidine. J Lipid Res 35: 1085-1092, 1994.
5. Dominiczak MH: Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin Chem Lab Med 41: 1266-1278, 2003.
6. Kilo C, Mezitis N, Jain R, Mersey J, McGill J and Raskin P: Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/ 30, or NPH insulin in combination with metformin. J Diabetes Complications 17: 307-313, 2003.
7. Lind DS: Arginine and cancer. Am Soc Nutr Sci J Nutr 134: 2837-2841, 2004.
8. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW and Mitchell JB: The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19: 711-721, 1998.
9. Nilsson BO: Biological effects of aminoguanidine: an update. Inflamm Res 48: 509-515, 1999.
10. Satriano J, Matsufuji S, Murakami Y, et al: Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem 273: 15313-15316, 1998.
11. Berlinck RG: Natural guanidine derivatives. Nat Prod Rep 19: 617-649, 2002.
12. Matsunaga K, Kazumichi H, Imamura T, Fujioka T, Takata J and Karube Y: Technetium labelling of dextran incorporating cysteamine as a ligand. Nucl Med Biol 32: 279-285, 2005.
13. Sakaguchi S: Uber eine neue farbenreaktion von protein und arginin. J Biochem 5: 25-31, 1925.
14. Weber CJ: A modification of Sakaguchi's reaction for the quantitative determination of arginine. J Biol Chem 86: 217-222, 1930.
15. Messineo L: Modification of the Sakaguchi reaction: spectro-photometric determination of arginine in proteins without previous hydrolysis. Arch Biochim Biophys 117: 538-540, 1966.
16. Van Pilsum JF, Martin RP, Kito E and Hess J: Determination of creatine, creatinine, arginine, guanidinoacetic acid, guanidine and methyl-guanidine in biological fluids. J Biol Chem 222: 225-236, 1956.
17. Larsson R and Nygren P: A rapid fluorometric method for semi-automated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 9: 1111-1119, 1989.
18. Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.
19. Maestre N, Tritton TR, Laurent G and Jaffrezou JP: Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kB activation but not apoptosis signaling. Cancer Res 61: 2558-2561, 2001.
20. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
21. Di Leo A and Moretti E: Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol 26: 5011-5013, 2008.
22. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
23. Welch JE, Bengtson P, Svensson K, et al: Single chain fragment anti-heparan sulfate antibody targets the polyamine transport system and attenuates polyamine-dependent cell proliferation. Int J Oncol 32: 749-756, 2008.
24. Criss WE: A review of polyamines and cancer. Turk J Med Sci 33: 195-205, 2003.
25. Holley JL, Mather A, Wheelhouse RT, Cullis PM, Hartley JA, Bingham JP and Cohen GM: Targeting of tumor cells and DNA by a chlorambucil-spermidine conjugate. Cancer Res 52: 4190-4195, 1992.
26. Zhang Y and Cremer PS: Interactions between macromolecules and ions: the Hofmeister series. Curr Opin Chem Biol 10: 658-663, 2006.